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Abstract
Background:  In recent years, numerous studies have assessed the prevalence of germline
mutations in BRCA1 and BRCA2 genes in various cohorts. We here extensively investigated the
prevalence and geographical distribution of BRCA1-2  mutations in the entire genetically-
homogeneous Sardinian population. The occurrence of phenotypic characteristics which may be
predictive for the presence of BRCA1-2 germline mutations was also evaluated.
Methods: Three hundred and forty-eight breast cancer patients presenting a familial recurrence
of invasive breast or ovarian carcinoma with at least two affected family members were screened
for BRCA1-2 mutations by DHPLC analysis and DNA sequencing. Association of BRCA1 and BRCA2
mutational status with clinical and pathological parameters was evaluated by Pearson's Chi-Squared
test.
Results and Conclusion: Overall, 8 BRCA1 and 5 BRCA2 deleterious mutations were detected in
35/348 (10%) families; majority (23/35;66%) of mutations was found in BRCA2  gene. The
geographical distribution of BRCA1-2 mutations was related to three specific large areas of Sardinia,
reflecting its ancient history: a) the Northern area, linguistically different from the rest of the island
Published: 20 July 2009
BMC Cancer 2009, 9:245 doi:10.1186/1471-2407-9-245
Received: 5 February 2009
Accepted: 20 July 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/245
© 2009 Palomba et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:245 http://www.biomedcentral.com/1471-2407/9/245
Page 2 of 10
(page number not for citation purposes)
(where a BRCA2 c.8764_8765delAG mutation with founder effect was predominant); b) the Middle
area, land of the ancient Sardinian population (where BRCA2 mutations are still more common than
BRCA1  mutations); and c) the South-Western area, with many Phoenician and Carthaginian
locations (where BRCA1 mutations are prevalent). We also found that phenotypic features such as
high tumor grading and lack of expression of estrogen/progesterone receptors together with age
at diagnosis and presence of ovarian cancer in the family may be predictive for the presence of
BRCA1-2 germline mutations.
Background
Breast cancer is the most common malignancy in women
in Western countries, currently accounting for one third of
all female cancers [1]. In Sardinia, breast cancer represents
the principal death-causing malignancy, with an inci-
dence similar to that observed in western countries [2].
Familial aggregation is thought to account for 5–10% of
all breast cancer cases, and germline mutations in differ-
ent genes involved in pathways critical to maintain the
genomic integrity have accounted for less than 25% of the
inherited breast cancer [3,4]. Part of this familial cluster-
ing shows autosomal dominant inheritance with high
penetrance due to mutations in the BRCA1  (MIM
113705) and BRCA2 (MIM 600185) breast cancer genes
[5,6]. Cumulative breast cancer risks by age 70 are esti-
mated to be 65% for BRCA1 and 45% for BRCA2 muta-
tion carriers. In addition, women with BRCA mutations
are at significant risk to develop ovarian cancer and other
malignancies [7].
Hundreds of mutations among breast/ovarian cancer
families have been found in these two genes. According to
the Breast Cancer Information Core (BIC) database [8,9],
about two thirds of germline variants identified in BRCA1
and BRCA2 are unique; the remaining ones are recurrent
founder mutations which have been described in different
ethnic groups and populations. Therefore, the mutation
spectrum and prevalence of mutation carriers with breast
or ovarian cancer depends on the population studied, and
displays considerable variation based on ethnic and geo-
graphical diversity. In Italy, 4–27% of the identified muta-
tions recurred among apparently unrelated families, while
a regional founder effect has been demonstrated for few
mutations [10-13]. In Sardinia, contribution of BRCA1-2
mutations to breast cancer predisposition has been
reported for populations from the Northern part of the
island [14]. Sardinian population shows strong founder
effects for several genetic diseases with some geographical
differences within the island [15,16]; indeed, some
genetic heterogeneity has been described within the
coastal or proximal-to-coast regions, which have suffered
repeated invasions over many years, in comparison to the
most internal and isolated part of the island [17]. On this
regard, the assessment of both spectrum and prevalence of
BRCA1 and BRCA2 mutations across the entire island as
well as their predictive significance in this population is
needed. Nevertheless, assessment of the likelihood of car-
rying deleterious mutations in BRCA1 or BRCA2 genes
among patients who present high-risk cancer evaluation
clinics will provide more accurate guidance to women and
families about considering genetic testing [7].
Here we report on the prevalence and geographical distri-
bution of BRCA1-2 mutations within the entire Sardinian
population. We also investigated the existence of any sig-
nificant association between mutations in BRCA1-2 genes
and phenotypic characteristics of breast cancer patients
that could drive specific treatment and influence the proc-
ess of mutation testing.
Methods
Family selection
A total of 1,085 unselected breast cancer patients was
recruited from all clinics at the Universities and Hospitals
across the Sardinia island. To avoid any bias, patients were
consecutively collected from January 1998 to December
2003 and were enrolled regardless of age at diagnosis,
family history status or disease features. Sardinian origin
was ascertained in all cases through genealogical studies.
Family history of cancer was evaluated through specific
questionnaires during the follow-up visits at the partici-
pating institutions. Three-hundred-forty-eight (32%) pre-
sented a familial recurrence of invasive breast or ovarian
carcinoma: 237 originated from North Sardinia, 66 from
Middle and 45 from South. Part of the present cohort
(112 familial cases with at least three affected members)
had been already included in our previous studies
[18,19]. The remaining 737 (68%) breast cancer patients
were sporadic cases.
Among patients with a family history of breast/ovarian
cancer, 131/348 (37.6%) fulfilled the selection criterion
for "high risk" families: presence of a breast cancer patient
diagnosed before age 50 years and having at least one first-
or second-degree relative diagnosed with breast cancer
before 50 years of age or ovarian cancer at any age.
Of those, 73 originated from North Sardinia, 21 from the
Middle and 37 from the South. The 81% of "high risk"
families presented with breast cancer and the 12% with
both breast and ovarian cancer. Male breast cancer was
present in the 7% of the families (Table 1). The remainingBMC Cancer 2009, 9:245 http://www.biomedcentral.com/1471-2407/9/245
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217 families were categorized as "no high risk" families:
presence of a breast cancer patient having at least one first-
or second-degree relative who is diagnosed with breast
cancer or ovarian cancer at any age.
According to number of breast/ovarian cancer in the fam-
ilies, we had 75 families with 3 or more affected members
and 47 families with two affected members among the
"high risk" cases; 67 families had 3 or more affected mem-
bers and 70 families had two affected members among the
"no high risk" cases. Information on total number of
affected family members were uncertain or not available
for 9 and 80 patients in the "high risk" and "no high risk"
groups, respectively.
Clinical and pathological characteristics of the breast can-
cer probands including age at diagnosis, mono- or bilat-
eral tumour location, stage of disease, tumour-node-
metastasis system status, tumour grading, estrogen/pro-
gesterone receptor status, were confirmed by medical
records and pathology reports.
Patients were informed about the aims of the study; blood
samples for genetic testing were drawn after obtaining
their written consent. The study was reviewed and
approved by the ethical review boards of the participating
Institutions accounting for samples' collection (University
of Sassari; Azienda Sanitaria Locale of Sassari, Nuoro and
Cagliari).
Mutation detection
Mutation analysis of coding sequences and intron-exon
boundaries of the BRCA1 and BRCA2 genes was carried
out in the series of 348 probands from families with
hereditary breast cancer. Genomic DNA was obtained
from isolated white blood cells by salting out procedure
[20]. Mutation detection for all coding regions and splice
boundaries of BRCA1 and BRCA2 genes was performed by
single strand conformation polymorphism (SSCP) for a
small fraction of cases (27 family probands); all remain-
ing cases underwent mutational screening by denaturing
high performance liquid chromatography (DHPLC),
using the WAVE Nucleic Acid Fragment Analysis System
(Transgenomic, Omaha, NE), followed by automated
sequencing as previously reported [18,19]. To confirm
that each germline variant detected by sequencing was a
real mutation and not a polymorphism, 103 unrelated
normal individuals (corresponding to 206 chromo-
somes), originating from the same geographical area and
with no family history for breast cancer, were used as con-
trols and screened for each gene variant identified. For
sequence homology searches, National Center for Bio-
technology Information Blast database http://
www.ncbi.nlm.nih.gov/BLAST/ has been used [21]. All
identified variants were verified for their existence and
nomenclature into the BIC database http://
research.nhgri.nih.gov/bic/ and the Human Gene Muta-
tion Database http://www.hgmd.cf.ac.uk/ac/[22-24].
Statistical Analysis
The Pearson's Chi-Squared test was used for assessing the
existence of any correlation between occurrence of delete-
rious germline mutations in BRCA1,  BRCA2, or either
gene and probands' characteristics. The following varia-
bles and categories were defined and included in our anal-
yses: presence of ovarian or male breast cancer in family,
synchronous or asynchronous bilateral breast carcinoma,
age at diagnosis, histological tumor grade as standardized
by Elston and Ellis [25], disease stage (pathological pri-
mary tumor size, pathological nodal status, presence of
metastases) according to TNM classification which
describes the anatomical extended of the disease by Sobin
et al [26], estrogen and progesterone receptor status. The
exact coefficient for sample proportion analysis was calcu-
lated to determine all of the significant parameters (below
the 0.05 level). Odds ratios of carrying BRCA1-2 muta-
tions were estimated by the logistic regression model and
reported with 95% confidence interval (95% CI). All anal-
yses were performed with the statistical package SPSS/7.5
for Windows.
Results
Family screening for BRCA1 and BRCA2 mutations
Genomic DNA from 348 probands of breast-ovarian can-
cer families was screened for germline mutations in
Table 1: BRCA1 and BRCA2 mutational analysis
Characteristics Cases BRCA positive Families
No. % No. %
TOTAL CASES* 348 35 10
"High risk" 131 23 17.5
BC 106 81 17 16.0
BC/OC 16 12 5 31.2
MBC 9 7 1 11.1
Age at diagnosis <40 y 41 31 12 29.2
"No High risk" 217 12 5.5
BC 204 94 11 5.4
BC/OC 8 4 1 12.5
MBC 5 2 0 0.0
2 BC/OC in the family 114 4 3.5
≥ 3 BC/OC in the family 145 17 11.7
High risk: presence of a breast cancer patient diagnosed before age 
50 years and having at least one first- or second-degree relative who 
is diagnosed with breast cancer before 50 years of age or ovarian 
cancer at any age). No high risk: presence of a breast cancer patient 
having at least one first- or second-degree relative who is diagnosed 
with breast cancer or ovarian cancer at any age. BC, breast cancer; 
OC, ovarian cancer; MBC, male breast cancer.
* including 112 families already reported in our previous studiesBMC Cancer 2009, 9:245 http://www.biomedcentral.com/1471-2407/9/245
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BRCA1 and BRCA2 genes. Overall, deleterious germline
mutations were detected in 35/348 (10%) familial cases:
23/131 (17.5%) among "high-risk" and 12/217 (5.5%)
among "no high-risk" families (Table 1). Families with 3
or more BC cases, including the 112 reported in our pre-
vious studies, showed a prevalence rate of 11.7% (17/
145). Presence of ovarian cancer in family increased the
occurrence of BRCA1-2 germline mutations in either the
subset of "high-risk" families (5/16; 31%) or the group of
"no high-risk" families (1/8; 12.5%). No similar variation
of mutation rates was observed in families presenting a
male member with breast cancer. Stratification of families
according to number of breast-ovarian cancer cases
showed that BRCA1/2 positivity was significantly higher
in families with 3 or more affected members than those
with only two cases, with frequencies of 11.7% and 3.5%,
respectively. Among 41/131 "high-risk" probands diag-
nosed at age ≤40 years, 12 (29%) presented a BRCA1-2
germline mutation.
The overall mutation prevalence was 7% in North Sar-
dinia and 17% and 18% in families from Middle and
South Sardinia, respectively. BRCA positivity accounts for
11% (8/73), 38% (8/21) and 19% (7/37) in "high risk"
families from these geographical areas (data not shown).
Spectrum of BRCA1-2 mutations in Sardinia
Overall, 8 distinct BRCA1 and 5 distinct BRCA2 patho-
genic mutations were found in 35 (10%) out of 348
breast-ovarian cancer families; 11 "high-risk" families
were positive for BRCA1 and 12 for BRCA2, whereas 1
BRCA1 and 11 BRCA2 mutations were identified in "no
high-risk" families. Therefore, majority (23/35; 66%) of
such mutations was found in BRCA2, and 12/35 (34%)
were in BRCA1. All mutations were absent in normal
genomic DNA from 103 unrelated healthy individuals
(corresponding to 206 control chromosomes) and were
classified as disease-causing variants due to their predicted
effects on proteins. In Table 2, all germline mutations
detected in our series have been reported. The BRCA1
c.916_917delTT  mutation was the most represented
BRCA1 variant (three positive families out of 348 cases;
1%), while the variants c.8764_8765delAG  and
c.3950_3952delTAGinsAT were the most recurrent muta-
tions in BRCA2 among patients with a positive family his-
tory [13/348 (4%) and 7/347 (2%), respectively]. These
mutations showed similar frequencies in both the "high
risk" and no "high risk" groups (6.8% vs 5%).
As indicated in Table 2, 4 out of 8 BRCA1 mutations and
2 out of 5 BRCA2 mutations have not been previously
Table 2: BRCA1 and BRCA2 pathogenetic mutationsa
N° of positive families GENE EXON DNA LEVEL PROTEIN LEVEL Mutation type BIC
1 BRCA1 5 c.300 T>G p.Cys61Gly missense YES
3 BRCA1 11 c.916_917delTT p.Val266SerfsX19 frameshift YES
1 BRCA1 11 c.1099_1100delCA p.Thr327fsX1 frameshift YES
1 BRCA1 11 c.1499insA p.Phe461fsX18 frameshift YES
2 BRCA1 11 c.1632 A>T p.Lys505X non sense NO
1 BRCA1 11 c.1638 A > T p.Arg507X non sense NO
2 BRCA1 11 c.3823_3826delACAA p.Asn1235fsX27 frameshift NO
1 BRCA1 14 c.4575delA p.Ser1486fsX18 frameshift NO
7 BRCA2 11 c.3950_3952delTAGinsAT p.Phe1241fsX17 frameshift NO
1 BRCA2 11 c.6586 C>G p.Ser2120X non sense NO
1 BRCA2 11 c.6023_6024delTA p.His1932X12 frameshift YES
13 BRCA2 20 c.8764_8765delAG p.2846X22 frameshift YES
1 BRCA2 18 c.8559+1G>T - splicing YES
a Consensus nomenclature of mutations according to den Dunnen and Antonarakis [22]. Mutations refer to the GenBank accession #BRCA1: no. 
U14680 and BRCA2: no. NM_000059).BMC Cancer 2009, 9:245 http://www.biomedcentral.com/1471-2407/9/245
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reported in either the BIC database. http://
research.nhgri.nih.gov/bic/ or in the Human Gene Muta-
tion Database http://www.hgmd.cf.ac.uk/ac/[23,24].
Besides deleterious mutations, complete BRCA1-2 screen-
ing identified 32 missense mutations and 16 intronic var-
iations: 21 already described polymorphisms, 14 variants
of unknown clinical significance and 13 novel variants
not reported in the BIC database (Table 3).
The geographical origin of the families positive for delete-
rious  BRCA1-2  mutations is shown in Figure 1. The
BRCA1 variants occurred in families originating from dif-
ferent areas of the island: 7 probands from the South, 2
from the Middle (BRCA1 c.3823_3826delACAA, BRCA1
c.300 T>G) and 1 from the North (BRCA1 c.1632 A>T).
Carriers of the BRCA1 c.916_917delTT mutation were
identified in three unrelated families from the South area.
Table 3: Other genetic variants in BRCA1 and BRCA2
Gene Exon Nucleotide Codon Intron Base change Mutation type Nomenclature BIC citation/Clinical importance
BRCA1 561–34 7 T > C IVS7-34 T>C YES/no
667–57 8 delT IVS8-57 delT YES/no
11 2196 693 G > A missense D693N YES/no
11 2731 871 C > T missense P871L YES/no
11 3232 1038 A > G missense E1038G YES/no
11 3667 1183 A > G missense K1183R YES/no
15 4654 1512 G > T missense S1512I YES/no
16 4956 1613 A > G missense S1613G YES/no
16 A > G IVS16-68 A>G YES/no
16 A > G IVS16-92 A>G YES/no
11 1186 356 A > G missense Q356R YES/unknown
11 1822 568 C > T missense P568L YES/unknown
11 2596 826 C > A missense T826K YES/unknown
11 4158 1347 A > G missense R1347G YES/unknown
11 4173 1352 G > A missense E1352K YES/unknown
16 5075 1652 G > A missense M1652I YES/unknown
17 C > T IVS17-53 C>T YES/unknown
18 G > A IVS18+65 G>A YES/unknown
5 287 56 A > T missense K56N NO/unknown
5 288 57 G > A missense G57R NO/unknown
17 G > T IVS17-53 G>T NO/unknown
20 T > C IVS20+34 T>C NO/unknown
22 5469 1784 G > A missense W1784I NO/unknown
BRCA2 5'UTR 203 G > A missense 203G>A YES/no
10 1379 384 C > T missense S384F YES/no
10 1093 289 A > C missense N289H YES/no
11 3199 991 A > G missense N991D YES/no
11 4469 1414 C > T missense T1414M YES/no
11 4486 1420 G > T missense D1420Y YES/no
16 T > C IVS16-14 T>C YES/no
20 8731 2835 T > C missense S2835P YES/no
22 21 T > C IVS21-66 T>C YES/no
27 10204 3326 A > T nonsense K3326X YES/no
1 353 42 C > T missense Y42C YES/unknown
10 1409 394 A > C missense E394A YES/unknown
11 3623 1132 A > G missense K1132R YES/unknown
11 6328 2034 C > T missense R2034C YES/unknown
11 6359 2044 G > C missense G2044A YES/unknown
25 24 T > C IVS24-16 T>C YES/unknown
10 1343 372 A > C missense W372N NO/unknown
2 G > A IVS2+65 G>A NO/unknown
4 A > C IVS4+67 A>C NO/unknown
1042 272 A > T missense N272I NO/unknown
11 5967 1910 A > T missense N1910I NO/unknown
14 C > T IVS14+53 C>T NO/unknown
14 7863 2546 T > C missense S2546P NO/unknown
16 7975 2583 G > A missense D2583N NO/unknown
16 T > A IVS16-32 T>A NO/unknownBMC Cancer 2009, 9:245 http://www.biomedcentral.com/1471-2407/9/245
Page 6 of 10
(page number not for citation purposes)
The  BRCA2 c.8764_8765delAG and BRCA2
c.3950_3952delTAGinsAT  variants were found in
probands from the North and Middle Sardinia, whereas
the remaining BRCA2  variants were detected in single
families from the Central-East coast and South.
Correlation between BRCA1-2 mutations and probands' 
phenotype characteristics
As shown in Table 4, univariate analysis indicated that
presence of a BRCA1-2 mutation correlated significantly
with earlier diagnosis age (P = 0.046), classification of the
family as "high risk" (P = 0.002), recurrence in the family
of ovarian cancer (P = 0.006), and development of a bilat-
eral disease (P = 0.038). Considering the pathological
parameters of primary tumors, no statistically significant
correlation between BRCA1-2  mutations and primary
tumor size (T) or axillary nodal status (N) or distant local-
ization of the disease (M) was observed. However, the
BRCA1-2 mutation rates were significantly higher in the
subsets of patients with a more undifferentiated primary
carcinoma (tumor grading 3–4, P < 0.001) and lack of
expression of estrogen receptor (ER-, P = 0.002) or proges-
terone receptor (PR-, P = 0.007).
Discussion
In this study, we have reported the prevalence of BRCA1-
2 germline mutations in patients with a positive family
history of breast and/or ovarian cancer from Sardinia,
whose population shows genetic peculiarity due to geo-
graphical isolation and strong genetic drift [27,28]. Preva-
lence of BRCA1-2  mutations may indeed vary among
distinct populations due to concurrence of different envi-
ronmental factors and genetic backgrounds; in other
words, patients origin may strongly account for different
mutation rates in candidate genes.
In the present study, a germline pathogenic mutation in
either BRCA1 or BRCA2 was identified in 10% of screened
breast-ovarian cancer families (BRCA1  mutations were
detected in about 3% of cases, while BRCA2 mutations
were identified in about 7% of families). BRCA positivity
reached 17.5% when considering the "high risk" families,
29% in families with probands diagnosed at age ≤40 years
and 31% in the presence of ovarian cancer in the family.
Prevalence rate in "high risk" families was higher than that
of families with 3 or more affected member regardless of
age at onset (11.7%). These results confirm that clinical
Table 4: Logistic regression analysis to identify predictors of BRCA mutations
Characteristics No. of cases BRCA+ carriers OR (95% CI) P
Age of Onset
< 45 years 139 21 (15%) 1.8 (1.05–4.28) 0.046
> 45 years 209 14 (7%)
Risk criteria
high-risk family 131 23 (18%) 3.2 (1.51–6.67) 0.002
no high risk family 217 12 (6%)
Ovarian cancer in family
presence 23 6 (26%) 3.7 (1.44–9.40) 0.006
absence 244 27 (11%)
Bilaterality
presence 36 8 (22%) 2.4 (1.05–5.39) 0.038
absence 228 25 (11%)
T
T1 151 12 (8%) 2.23 (0.57–8.82) 0.251
T2 70 10 (14%)
T3-4 26 4 (15%)
N
N- 126 15 (12%) 1.02 (0.39–2.67) 0.963
N+ 112 13 (12%)
M
M0 201 20 (10%) 1.33 (0.15–11.7) 0.797
M1 24 3 (12%)
Tumor Grading
G1-2 171 9 (5%) 11.3 (3.38–37.6) < 0.001
G3-4 33 12 (36%)
Estrogen Receptor (ER)
ER- 55 16 (29%) 0.18 (0.06–0.53) 0.002
ER+ 102 10 (10%)
Progesteron Receptor (PR)
PR- 81 21 (26%) 0.22 (0.07–0.66) 0.007
PR+ 67 6 (9%)BMC Cancer 2009, 9:245 http://www.biomedcentral.com/1471-2407/9/245
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characteristics such as ovarian cancer in the family, age at
diagnosis and number of cases are good predictors for the
likelihood to be a BRCA mutation carrier.
The overall prevalence of BRCA1-2  mutations among
breast cancer patients from the entire Sardinia was quite
similar to that previously reported for breast-ovarian can-
cer families originating from the Northern part of the
island (for both studies, 15% BRCA-positive carriers were
observed in breast-ovarian cancer families [14,18]. How-
ever prevalence of BRCA deleterious mutations was higher
in Middle Sardinia (38% vs 11% in the North. and 19%
in the South). When compared to many other Italian and
European studies, the frequency is relatively low [10-
13,29-32]. Since the sensitivity of mutation detection
methods is not complete, some mutations may have
remained undetected in the present study. Large genomic
deletions, which do escape detection by both DHPLC and
direct sequencing may account for a fraction of mutation-
negative breast and ovarian cancer families in Sardinia.
Overall and even considering a lack of sensitivity of the
screening approach used in the present study, the preva-
lence of BRCA mutations in Sardinian families remains
low. The selection criterion of two close relatives with
breast cancer before the age of 50 years, used in this study,
may somehow explain this low prevalence rate, though it
is not possible to exclude that a specific genetic back-
ground may play a role on breast cancer susceptibility
among Sardinian population. Noteworthy, a similar low
prevalence of BRCA mutations was reported in the Finn-
ish population which has genetic features comparable to
the Sardinian one, where the historical, cultural and geo-
graphical isolation may have selected specific genetic var-
iants as susceptibility genes for breast cancer [33].
The geographical origin of the families positive for delete-
rious  BRCA1-2  mutations is shown in Figure 1. The
BRCA2 c.8764_8765delAG and c.3950_3952delTAGinsAT
variants were previously described as founder mutations
in North and Middle Sardinia, respectively. In particular,
cases carrying the BRCA2 c.8764_8765delAG mutation
belonged to unrelated families originating from different
villages in the northern part of the island [11,14]; most of
families genotyped with markers flanking the BRCA2 gene
at 13q12-q13 locus were demonstrated to share a large
haplotype, not found in control chromosomes from the
same geographical area [11]. Conversely, the BRCA2
c.3950_3952delTAGinsAT, which was previously reported
as a founder mutation, was instead running in families
belonging to a single extended pedigree confined to a
small village of the central part of Sardinia [19]. The
BRCA1 variants occurred in families originating from dif-
ferent areas of the island without a defined geographical
clustering, though about half of the cases carrying the
BRCA1  mutations originated from the South Sardinia.
Interestingly, in three unrelated families from the South
and Middle Sardinia we identified carriers of the BRCA1
c.916_917delTT  mutation that has been reported in
breast-ovarian cancer families from South Italy [34]. Alto-
gether, the geographical distribution of the genetic vari-
ants in the island, suggests that BRCA1-2 mutations are
related to the specific three large areas of Sardinia, which
Geographical distribution of BRCA1-2 mutations carriers in  Sardinia Figure 1
Geographical distribution of BRCA1-2 mutations car-
riers in Sardinia. Symbols indicate villages of origin for the 
patients presenting deleterious germline mutations in either 
BRCA1 or BRCA2 genes: "green square" BRCA1 c.300 T>G; 
green circle BRCA1 c.916_917delTT; "green triangle" BRCA1 
c.1099_1100delCA; "green arrow" BRCA1c.1499insA; "green 
heart"BRCA1 c.1632 A>T; "green diamond" BRCA1 c.1638 
A>T;"green clubs" BRCA1 c.3823_3826delACAA; "green 
spades" BRCA1 c.4575delA; "blue square" BRCA2 
c.3950_3952delTAGinsAT; "blue triangle" BRCA2 c.6586 
C>G; "blue circle" BRCA2 c.6023_6024delTA; "blue arrow" 
BRCA2 c.8764_8765delAG; "blue heart"BRCA2 c.8559+1G>T. 
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reflects its ancient history: a) the North area, delimited by
the mountain chain crossing Sardinia and linguistically
different from the rest of the island (where the
c.8764_8765delAG variant acts as founder mutation); b)
the Middle area, land of the ancient Sardinian population
and domain of pastoral culture (where BRCA2 mutations
are still more common than BRCA1 mutations); and c)
the South-West area, with many Phoenician and Carthag-
inian archeological sites (where BRCA1  mutations are
prevalent).
Majority of BRCA1-2  germline mutations identified in
Sardinian families is unique: most of the variants were
detected in single families and 6 were novel mutations.
The frequencies of BRCA1 or BRCA2 mutations among
breast-ovarian cancer families varies widely between pop-
ulations world-wide: Icelandic breast cancer families
present almost exclusively BRCA2  mutations [30],
roughly equal numbers of BRCA1 and BRCA2 mutations
have been described in French Canadian or British breast
cancer families [35,36], while a clear prevalence of BRCA1
mutations has been observed in the United States [37,38].
In this study BRCA2 mutations were more frequent than
BRCA1  mutations, although it should be taken into
account that a high proportion of families are carrying the
BRCA2 c.8764_8765delAG founder mutation. Mutations
in BRCA2 gene have been detected in up to 40% of male
breast cancers in Iceland [39]; in our isolated population,
we detected a BRCA2 mutation in 1/14 (7%) men with
breast cancer with a frequency similar to that reported for
male breast cancers in USA (4%) [40]. Again, these find-
ings suggest that other environmental and/or genetic fac-
tors are contributing to the susceptibility to male breast
cancer in Sardinia.
Specific pathological features have been reported in
hereditary breast cancer with differences between BRCA1
and BRCA2 associated tumors [41]. In our series, the anal-
ysis of clinico-pathological characteristics showed some
differences between BRCA1-2 wild type and mutation car-
riers. Though no correlation with the stage of disease (the
main prognostic factor for breast cancer patients) was
observed, the presence of BRCA1-2 mutations were signif-
icantly associated with some pathological characteristics
(higher tumor grading, lack of expression of estrogen/pro-
gesterone receptors) which are recognized to have a nega-
tive impact on prognosis. Unfortunately, data from
mutation screening of BRCA1 and BRCA2 were combined
for the statistical analysis due to the low number of posi-
tive cases for each single gene in our series, although dis-
tinct differences in both molecular pathology and
histopathology have been shown according to the specific
carrier status.
Conclusion
In summary, our results on the entire Sardinian popula-
tion demonstrated that: a) prevalence of BRCA1  and
BRCA2 mutations is 10% in familial breast-ovarian can-
cer; b) the spectrum of mutations among Sardinians is
unique; c) some specific phenotypic features may be pre-
dictive for the presence of BRCA1-2 germline mutations
and should be therefore considered when counselling Sar-
dinian patients about undergoing genetic testing. On this
regard, the fulfilment of one or more of the following cri-
teria seems to increase the probability to detect a predis-
posing BRCA1-2 mutation among Sardinian breast cancer
patients: a) high-risk classification of the patient's family;
b) presence of at least one family member with ovarian
cancer;  c) occurrence of synchronous or asynchronous
bilateral breast carcinoma.
Our findings further confirm that mutation frequency for
BRCA1  and  BRCA2  as cancer susceptibility genes for
breast-ovarian carcinoma needs to be evaluated in each
distinct geographical area. Finally, the absence of any
BRCA1  or  BRCA2  mutation in majority of "high-risk"
families with breast-ovarian cancer support the general
hypothesis that additional breast cancer susceptibility
genes remain to be identified.
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